-+ 0.00%
-+ 0.00%
-+ 0.00%

Wolfe Research Downgrades Intellia Therapeutics to Underperform, Announces $9 Price Target

Benzinga·07/16/2026 10:42:27
语音播报
Wolfe Research analyst Andy Chen downgrades Intellia Therapeutics (NASDAQ:NTLA) from Peer Perform to Underperform and announces $9 price target.